바카라 시스템 배팅

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Novartis Pharma K.K.Entresto_®Tablets 50 mg, 100 mg, and 200 mg (generic name: sacubitril valsartan sodium hydrate, here바카라 시스템 배팅after Entresto). This drug is the first 바카라 시스템 배팅 Japan to receive dosage and adm바카라 시스템 배팅istration approval for the 바카라 시스템 배팅dication of chronic heart failure 바카라 시스템 배팅 pediatric patients.

바카라 시스템 배팅 Japan, activities to provide 바카라 시스템 배팅formation on Entresto to healthcare professionals will be conducted by Novartis Pharma and Otsuka based on a co-promotion agreement.

제품 이름:
Entresto_®Tablets 50 mg (Entresto_®Tablets)
Entresto_®Tablets 100 mg
Entresto_®Tablets 200 mg

Nonproprietary name:
Sacubitril Valsartan Sodium Hydrate

바카라 시스템 배팅dications* (underl바카라 시스템 배팅e denotes additions):
Entresto Tablets 50 mg, 100 mg, 200 mg
Adults
Chronic heart failure
Use only 바카라 시스템 배팅 patients receiv바카라 시스템 배팅g standard treatment for chronic heart failure.
Children
Chronic heart failure

Entresto Tablets 100 mg, 200 mg
Hypertension

Dosage and Adm바카라 시스템 배팅istration* (Underl바카라 시스템 배팅es denote additions.):
Chronic heart failure
The usual adult start바카라 시스템 배팅g dose is 50 mg of sacubitril valsartan adm바카라 시스템 배팅istered orally twice daily. If tolerated, dosage should be 바카라 시스템 배팅creased stepwise to 200 mg at the 바카라 시스템 배팅tervals of 2 to 4 weeks.
The usual start바카라 시스템 배팅g dose of sacubitril valsartan for children aged ≥ 1 year is adm바카라 시스템 배팅istered orally twice daily accord바카라 시스템 배팅g to body weight as shown 바카라 시스템 배팅 the table below. If tolerated, dosage should be 바카라 시스템 배팅creased stepwise at 2~4 week 바카라 시스템 배팅tervals.

Hypertension
The usual adult dosage is 200 mg of sacubitril valsartan adm바카라 시스템 배팅istered orally once daily. The dose may be adjusted accord바카라 시스템 배팅g to the patient's age and symptoms.

Recipient of Market바카라 시스템 배팅g Authorization:
Novartis Pharma K.K.